Cargando…

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

BACKGROUND: Predicting metastasis in melanoma patients is important for disease management and could help to identify those who might benefit from adjuvant treatment. The aim of this study was to investigate whether the tumor microenvironment-derived protein S100A8/A9 qualifies as prognostic marker...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wagner, Nikolaus B., Weide, Benjamin, Gries, Mirko, Reith, Maike, Tarnanidis, Kathrin, Schuermans, Valerie, Kemper, Charlotte, Kehrel, Coretta, Funder, Anne, Lichtenberger, Ramtin, Sucker, Antje, Herpel, Esther, Holland-Letz, Tim, Schadendorf, Dirk, Garbe, Claus, Umansky, Viktor, Utikal, Jochen, Gebhardt, Christoffer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896585/ https://www.ncbi.nlm.nih.gov/pubmed/31806053 http://dx.doi.org/10.1186/s40425-019-0828-1

Ejemplares similares

The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
por: Umansky, Viktor, et al.
Publicado: (2016)

Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response
por: Bernhardt, Mathias, et al.
Publicado: (2017)

Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia: Case Report
por: Orouji, Elias, et al.
Publicado: (2014)

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
por: Sucker, Antje, et al.
Publicado: (2017)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
por: Reinhard, Raphael, et al.
Publicado: (2018)

Expression of Neural Crest Markers GLDC and ERRFI1 is Correlated with Melanoma Prognosis
por: Jäger, Katharina, et al.
Publicado: (2019)

Artificial Intelligence in Skin Cancer Diagnostics: The Patients' Perspective
por: Jutzi, Tanja B., et al.
Publicado: (2020)

Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations
por: Cosgarea, Ioana, et al.
Publicado: (2017)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients
por: Schrama, David, et al.
Publicado: (2014)

Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA
por: Stiller, Mathias, et al.
Publicado: (2016)

Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies
por: Utikal, Jochen, et al.
Publicado: (2007)

Lack of SF3B1 R625 mutations in cutaneous melanoma
por: Schilling, Bastian, et al.
Publicado: (2013)

Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcripts
por: Xie, Huaping, et al.
Publicado: (2016)

Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?
por: Tolle, Fabrice, et al.
Publicado: (2021)

Optimal experimental designs for dose–response studies with continuous endpoints
por: Holland-Letz, Tim, et al.
Publicado: (2014)

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
por: Ozbay Kurt, Feyza Gul, et al.
Publicado: (2023)

T-Cell Mediated Immune Responses Induced in ret Transgenic Mouse Model of Malignant Melanoma
por: Abschuetz, Oliver, et al.
Publicado: (2012)

Loss of tumorigenic potential upon transdifferentiation from keratinocytic into melanocytic lineage
por: Fehrenbach, Sabrina, et al.
Publicado: (2016)

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
por: Groth, Christopher, et al.
Publicado: (2018)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

Association of Inherited Variation in Toll-Like Receptor Genes with Malignant Melanoma Susceptibility and Survival
por: Gast, Andreas, et al.
Publicado: (2011)

TERT Promoter Mutations Are Frequent in Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma
por: Griewank, Klaus G., et al.
Publicado: (2013)

Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
por: Gassenmaier, Maximilian, et al.
Publicado: (2021)

Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity
por: Thier, Beatrice, et al.
Publicado: (2022)

The shedded ectodomain of Lyve-1 expressed on M2-like tumor-associated macrophages inhibits melanoma cell proliferation
por: Dollt, Claudia, et al.
Publicado: (2017)

B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis
por: Ugurel, Selma, et al.
Publicado: (2007)

SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma
por: Willmes, Christoph, et al.
Publicado: (2016)

BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
por: Peiffer, Lukas, et al.
Publicado: (2020)

Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
por: Fleming, Viktor, et al.
Publicado: (2018)

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
por: Weber, Rebekka, et al.
Publicado: (2018)

Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles
por: Arkhypov, Ihor, et al.
Publicado: (2020)

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs
por: Lepper, Alisa, et al.
Publicado: (2023)

Monocytic myeloid-derived suppressor cells in advanced melanoma patients: Indirect impact on prognosis through inhibition of tumor-specific T-cell responses?
por: Martens, Alexander, et al.
Publicado: (2014)

Influence of Genetic Variants in Type I Interferon Genes on Melanoma Survival and Therapy
por: Lenci, Romina Elizabeth, et al.
Publicado: (2012)

Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma
por: Federico, Aniello, et al.
Publicado: (2020)

A new efficient trial design for assessing reliability of ankle-brachial index measures by three different observer groups
por: Endres, Heinz G, et al.
Publicado: (2006)

Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma
por: Ammann, Nadine L., et al.
Publicado: (2022)

ADCK2 Knockdown Affects the Migration of Melanoma Cells via MYL6
por: Vierthaler, Marlene, et al.
Publicado: (2022)

Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses
por: Shevchenko, Ivan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n80vul0tf0l9anc9dnim776vv9